Cleared for final review, Aquestive Therapeutics received a March 16, 2027, FDA decision date for Anaphylm. The drug aims to be the first oral rescue medication for severe allergic reactions, with market relevance focused on the biopharmaceutical antiallergy sector and commercial launch readiness.